Invention Grant
- Patent Title: Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
-
Application No.: US14832103Application Date: 2015-08-21
-
Publication No.: US09610249B2Publication Date: 2017-04-04
- Inventor: Joseph G. Reynolds , Kenneth J. Olivier, Jr. , Bart S. Hendriks , Thomas Wickham , Stephan Klinz , Elena Geretti
- Applicant: MERRIMACK PHARMACEUTICALS, INC.
- Applicant Address: US MA Cambridge
- Assignee: Merrimack Pharmaceuticals. Inc.
- Current Assignee: Merrimack Pharmaceuticals. Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Honigman Miller Schwartz and Cohn LLP
- Agent Fernando Alberdi; Cynthia M. Bott
- Main IPC: A61K9/127
- IPC: A61K9/127 ; A61K31/7042 ; A61K47/48 ; A61K31/704 ; A61K47/42 ; G01N33/566 ; A61K9/00
Abstract:
Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
Public/Granted literature
Information query
